WEBINAR

Repurposing in a crisis: Tackling the COVID-19 wildfire

RUNNING ON-DEMAND NOW
DDN_logo_reverse-100

At ASMS 2019, SCIEX made a technology announcement of Acoustic Ejection Mass Spectrometry (AEMS) which will shortly be commercialized as Echo® MS in early 2020.

This webinar will provide insights into the fundamentals of the technology and how it harnesses the two unique technologies, Acoustic Droplet Ejection (ADE) and the Open Port Interface (OPI), combined with the quantitative power of SCIEX mass spectrometry. Read More Below

Register for the Webinar

Already registered?
Access the webinar here »

While the race for a vaccine targeting the SARS-CoV-2 coronavirus is expected to take another year or so, there is an increasingly urgent need to fight the disease in those already infected. Our upcoming webinar on COVID-19 will tackle the unique challenges of accelerating drug development by repurposing existing therapies where each day missed equals lives lost.

Speaker Information:

Nevan Krogan headshot-1

Nevan Krogan, PhD
Professor, Cellular & Molecular Pharmacology, University of California, San Francisco
Director, Quantitative Biosciences Institute, UCSF School of Pharmacy

SARS-CoV-2 protein interaction map reveals targets for drug repurposing

To find antiviral drugs versus SARS-CoV-2, it helps to understand how viral and human proteins interact.

DDN_COVID Webinar_200602_Sumit Chanda

Sumit Chanda, PhD
Director, Immunity & Pathogenesis Program, Sanford Burnham Presbys Medical Discovery Institute

Identifying inhibitors of SARS-CoV-2 replication by profiling a library of known drugs

To potentially shorten the development of antivirals against COVID-19, it is helpful to start with a panel of well-characterized leads. 

Sponsored by

ProQinase -Covid - Webinar -June 2 2020.png    R&D -Webinar June 2 logo -BT_BT-main-logo-spot-color-blue-1    synthego-logo-black-w-background@2x  twist-full-logo-transparent-250x130_copy

Interested in sponsoring a webinar?
Click here to contact our friendly sales team.